Cite
HARVARD Citation
Westphal, M. et al. (n.d.). A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. European journal of cancer. 51 (4), pp. 522-532. [Online].